Cevimeline for the Treatment of Postirradiation Xerostomia in Patients With Head and Neck Cancer

Conclusion: Cevimeline was well tolerated by patients with xerostomia after radiotherapy for head and neck cancer, and oral administration of 30-45 mg of cevimeline three times daily increased unstimulated salivary flow.